Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Researchers highlight ‘questionable’ data in Russian coronavirus vaccine trial results

Open letter flags results that appear to be duplicated and calls for access to the underlying data on the first COVID-19 vaccine to be approved for widespread use.
  1. Alison Abbott
    View author publications

    You can also search for this author in PubMed  Google Scholar

A group of researchers have expressed concern about repetitive patterns of data in a paper describing early-phase clinical trials of Russia’s coronavirus vaccine — the first jab worldwide to be approved for widespread use.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 585, 493 (2020)

doi: https://doi.org/10.1038/d41586-020-02619-4

Updates & Corrections

  • Correction 15 September 2020: An earlier version of this story mistakenly said that the open letter was published in The Lancet.

References

  1. Logunov, D. Y. et al. Lancet https://doi.org/10.1016/S0140-6736(20)31866-3 (2020).

    PubMed  Google Scholar 

  2. Folegatti, P. M. et al. Lancet 396, 467–478 (2020).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links